Medication info
Olostat 10/10 mg (Olmesartan Medoxomil, Rosuvastatin)

Olostat 10/10 mg (Olmesartan Medoxomil, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletOlmesartan Medoxomil›10mg / 1 tablet
Manufacturer / importer
(Co., Ltd. Daewoong Pharmaceutical)
Appearance
Light pink circular film-coated tablet
Packaging
30 tablets (10 tablets/PTP) x 3, 30 tablets/bottle
Approval status
Active

MFDS item code 201506871 · Approved 2015.09.30 · Insurance code 641606170

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have intravascular volume depletion (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while monitoring their condition closely. 2. Elderly patients No dosage adjustment is required when this medicine is administered to elderly patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dosage adjustment is required. 3. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Children under 18 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
(Co., Ltd. Daewoong Pharmaceutical)

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • coronary artery disease
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medicine is used for patients who need to take both components, Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil is effective primarily for the treatment of essential hypertension. Rosuvastatin is used as an adjunct for the treatment of primary hypercholesterolemia and mixed hyperlipidemia that cannot be controlled by diet and exercise alone. It also aids in lipid control for patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. It contributes to the reduction of risks associated with stroke, myocardial infarction, and revascularization in older patients at high risk for cardiovascular diseases. This medication improves cardiovascular health by managing both hypertension and hyperlipidemia simultaneously.

How to take

Adult dose

This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have intravascular volume depletion (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while monitoring their condition closely. 2. Elderly patients No dosage adjustment is required when this medicine is administered to elderly patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dosage adjustment is required. 3. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Children under 18 years: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm or even death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be used by individuals with allergies to this medication or its components, pregnant women or women of childbearing age, nursing mothers, patients undergoing dialysis, patients with severe renal insufficiency, patients with severe liver impairment, patients with biliary obstruction, patients with unexplained liver dysfunction, and patients with muscle diseases. Particularly, high doses of rosuvastatin may pose a higher risk of muscle damage, so patients with reduced kidney function, hypothyroidism, or a history of genetic muscle disorders should be cautious. This medication contains lactose and should not be given to patients with lactose intolerance or related genetic disorders. When this medication is first administered to patients with reduced blood volume or salt, hypotensive symptoms may occur, so their condition should be closely monitored, and appropriate action should be taken if hypotension occurs. This medication may affect kidney function; therefore, patients with renal impairment or those who have had a kidney transplant should have their kidney function and electrolyte status regularly checked by blood tests. Due to the risk of hyperkalemia, especially in heart failure or renal impairment patients, blood potassium levels should be closely monitored. Particular care is required when using this medication on patients with aortic stenosis or obstructive heart disease. This medication may cause dizziness due to its blood pressure-lowering effects; therefore, caution is needed when operating machinery or performing high-risk tasks, such as driving. Patients with a history of liver disease or excessive alcohol intake should undergo regular liver function tests; if liver function abnormalities arise, treatment should be discontinued immediately. Muscle pain, myopathy, and rarely rhabdomyolysis may occur; therefore, patients should immediately report any occurrence of muscle pain, weakness, or cramps to their healthcare provider for necessary testing. This medication may interact with other drugs, so especially when taking potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, and fibrates, it is essential to consult a specialist. Women who are pregnant or planning to become pregnant must strictly use proper contraceptive methods, and if pregnancy is confirmed, the medication should be discontinued immediately. Nursing mothers should either stop breastfeeding or discontinue this medication while taking it, and safety for pediatric patients and adolescents under 18 years of age has not been established. Elderly patients may have increased blood concentrations of this drug, thus requiring dosage adjustment and monitoring. In cases of overdose, symptoms such as hypotension, palpitations, and bradycardia may occur; appropriate treatment should be provided based on the symptoms. This medication should be kept out of reach of children, and it is advisable not to transfer it to another container. If any abnormal symptoms or discomfort occur during the use of this medication, it is crucial to consult a healthcare professional immediately to receive appropriate action.

Side effects

Increased ALT, Increased AST, Increased serum creatinine, Decreased creatinine clearance, Headache, Dizziness, Sensory loss, Neuromyopathy, Drowsiness, Reflux esophagitis, Constipation, Dental caries, Dyspepsia, Gastrointestinal ulcer, Gastritis, Gastroenteritis, Musculoskeletal stiffness, Atrial fibrillation, Hypoglycemia, Chest pain, Tooth extraction, Chest discomfort, Peripheral edema, Lightheadedness, Abdominal pain, Nausea, Palpitations, Hypercholesterolemia, Hyperlipidemia, Hyperuricemia, Arthralgia, Arthritis, Myalgia, Rash, Facial edema, Asthenia, Angioedema, Anaphylactic reaction, Vomiting, Chronic malabsorption syndrome, Intestinal vascular edema, Rhabdomyolysis, Hyperkalemia, Acute renal failure, Hair loss, Pruritus, Urticaria, Autoimmune hepatitis, Dizziness (including positional dizziness), Palpitations, Increased blood pressure, Low back pain, Diarrhea, Cough, Epistaxis, Upper respiratory infection, Asthma, Thrombocytopenia, Jaundice, Hepatitis, Stevens-Johnson syndrome, Eosinophilia with systemic symptom drug reaction syndrome, Polyneuropathy, Amnesia, Peripheral neuropathy, Dyspnea, Myopathy, Lupus-like syndrome, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Interstitial lung disease, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Cognitive impairment, Severe muscle weakness, Oculomotor weakness, Myalgia, Myopathy, Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, therefore, it must be stored in a tightly sealed container. It is also important to keep it at room temperature between 1°C and 30°C to maintain the drug's efficacy.

Appearance and packaging

Appearance

Light pink circular film-coated tablet

Package unit

30 tablets (10 tablets/PTP) x 3, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.